Intraperitoneal chemotherapy in the management of ovarian cancer
Abstract
During the past decade, intraperitoneal therapy of ovarian cancer has evolved from a pharmacologic model into an established treatment technique for women with this malignancy. Approximately 40% of patients with small‐volume residual ovarian cancer (microscopic disease or macroscopic tumor, ≤ 0.5 cm in maximum tumor diameter), after an objective response to initial organoplatinum‐based systemic chemotherapy, may have a surgically documented complete response to platinum‐based intraperitoneal chemotherapy. Patients who have not responded to systemic platinum administration rarely will respond to the drug given intraperitoneally, despite the presence of only small‐volume residual disease when this regional treatment strategy is used. Other agents with antineoplastic activity after intraperitoneal administration in women with ovarian cancer include mitoxantrone, taxol, alpha‐interferon and gamma‐interferon, and interleukin‐2. Although intraperitoneal therapy currently is being examined as a component of the initial chemotherapeutic program for patients with ovarian cancer, a precise role for regional drug delivery in this clinical setting remains to be defined.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Partial systemic restriction of intraperitoneal administration resulted in reduced toxicity and treatment-related complications.
“Furthermore, the partial systemic restriction of intraperitoneal administration resulted in reduced toxicity and treatment-related complications (44–46).”
From CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy (2020) · cites this paper as [44]
Cites
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100 · see citing works
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Rl, D., Ce, M., Bungay, P. M., & Vt, D. (1978) · PubMed · Cited by 735 · see citing works
Intraperitoneal Cisplatin with Systemic Thiosulfate Protection
Howell, S. B., PFEIFLE, C. L., WUNG, W. E., Olshen, R. A., LUCAS, W. E., YON, J. L., & GREEN, M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-6-845 · Cited by 484 · see citing works
THE ROUTE OF ABSORPTION OF INTRAPERITONEALLY ADMINISTERED COMPOUNDS
Lukas, G., Brindle, S. D., & Greengard, P. (1971) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28988-1 · Cited by 390 · see citing works
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Rowinsky, E. K., Donehower, R. C., Jones, R. J., & Tucker, R. W. (1988) · PubMed · Cited by 370 · see citing works
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Markman, M. M., Rowinsky, E. K., Hakes, T. B., Reichman, B. S., Jones, W., Lewis, J. L., Rubin, S. C., Curtin, J. P., Barakat, R. R., & Phillips, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.9.1485 · Cited by 312 · see citing works
Self-citationPharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.
Ozols, R. F., Locker, G. Y., Doroshow, J. H., Grotzinger, K. R., Myers, C. E., & Young, R. C. (1979) · PubMed · Cited by 248 · see citing works
Ozols, R. F., Young, R. C., Speyer, J. L., Sugarbaker, P. H., Greene, R. F., Jenkins, J., & Myers, C. E. (1982) · PubMed · Cited by 226 · see citing works
Howell, S. B., Zimm, S., Markman, M. M., ABRAMSON, I. S., Cleary, S., Lucas, W. E., & Weiss, R. J. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1607 · Cited by 220 · see citing works
Self-citationLos, G., Mutsaers, P. H. A., van der Vijgh, W. J. F., Baldew, G. S., de Graaf, P. W., & McVie, J. G. (1989) · PubMed · Cited by 205 · see citing works
Los, G., Verdegaal, E. M. E., Mutsaers, P. H. A., & McVie, J. G. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685503 · Cited by 195 · see citing works
Markman, M. M., Reichman, B. S., Hakes, T. B., Jones, W., Lewis, J. L., Rubin, S. C., Almadrones, L., & Hoskins, W. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1801 · Cited by 191 · see citing works
Self-citationBerek, J. S., Hacker, N. F., Lichtenstein, A. K., Jung, T., Spina, C. A., Knox, R. M., Brady, J., Greene, T., Ettinger, L. M., & Lagasse, L. D. (1985) · PubMed · Cited by 183 · see citing works
USE OF NITROGEN MUSTARD IN TREATMENT OF SEROUS EFFUSIONS OF NEOPLASTIC ORIGIN
Weisberger, A. S., Levine, B., & Storaasli, J. P. (1955) · JAMA · doi:10.1001/jama.1955.02960350004002 · Cited by 182 · see citing works
Theoretical and experimental bases of intraperitoneal chemotherapy.
Rl, D. (1985) · PubMed · Cited by 177 · see citing works
Bergman, F. (1966) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016346609158447 · Cited by 171 · see citing works
West, G. W., Weichselbaum, R. W., & Little, J. B. (1980) · PubMed · Cited by 155 · see citing works
Chemotherapy of non-small-cell lung cancer.
Ds, A., Young, L., Mason, N., & Salmon, S. E. (1985) · PubMed · Cited by 147 · see citing works
Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro.
Durand, R. E. (1981) · PubMed · Cited by 133 · see citing works
Casper, E. S., Dp, K., Nw, A., & Jl, L. (1983) · PubMed · Cited by 131 · see citing works
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics
Dunnick, N. R., Jones, R., Doppman, J., Speyer, J. L., & Ce, M. (1979) · American Journal of Roentgenology · doi:10.2214/ajr.133.2.221 · Cited by 114 · see citing works
Pharmacokinetics of carboplatin after intraperitoneal administration
Elferink, F., van der Vijgh, W. J. F., Klein, I., Huinink, W. W. T. B., Dubbelman, R., & McVie, J. G. (1988) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00262740 · Cited by 97 · see citing works
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Reichman, B. S., Markman, M. M., Hakes, T. B., Hoskins, W. J., Rubin, S. C., Jones, W., Almadrones, L., Ochoa, M., Chapman, D. S., & Saigo, P. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1327 · Cited by 89 · see citing works
Self-citationMarkman, M. M., Reichman, B. S., Hakes, T. B., Lewis, J. L., Jones, W., Rubin, S. C., Barakat, R. R., Curtin, J. P., Almadrones, L., & Hoskins, W. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.9.1479 · Cited by 86 · see citing works
Self-citationPenetration and binding of vinblastine and 5-fluorouracil in cellular spheroids
Nederman, T., & Carlsson, J. (1984) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257130 · Cited by 78 · see citing works
Intracavitary 5-Fluorouracil in Malignant Effusions
Suhrland, L. G. (1965) · Archives of Internal Medicine · doi:10.1001/archinte.1965.03870030111019 · Cited by 74 · see citing works
Speyer, J. L., Beller, U., Colombo, N., Sorich, J., Wernz, J., Höchster, H. S., Green, M., Porges, R. F., Muggia, F. M., & Canetta, R. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.8.1335 · Cited by 73 · see citing works
Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.
Markman, M. M., George, M., Hakes, T. B., Reichman, B. S., Hoskins, W. J., Rubin, S. C., Jones, W., Almadrones, L., & Lewis, J. L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.146 · Cited by 68 · see citing works
Self-citationSmall cell carcinoma cell lines contain opioid peptides and receptors
Roth, K. A., & Barchas, J. D. (1986) · Cancer · doi:10.1002/1097-0142(19860215)57:4 · Cited by 66 · see citing works
Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.
Pretorius, R. G., Hacker, N. F., Berek, J. S., Ford, L. C., Hoeschele, J. D., Butler, T. A., & Lagasse, L. D. (1983) · PubMed · Cited by 65 · see citing works
Piver, M. S., Lele, S. B., Marchetti, D. L., Baker, T. R., Emrich, L. J., & Hartman, A. B. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.11.1679 · Cited by 64 · see citing works
Alberts, D. S., Surwit, E. A., Peng, Y. M., McCloskey, T. M., Rivest, R. S., Graham, V. M., McDonald, L., & Roe, D. J. (1988) · PubMed · Cited by 62 · see citing works
DeGregorio, M. W., Lum, B., Holleran, W. M., Wilbur, B. J., & Sikic, B. I. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00273393 · Cited by 59 · see citing works
A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
DʼAcquisto, R. W., Markman, M. R., Hakes, T. B., Rubin, S. C., Hoskins, W. J., & Lewis, J. L. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.689 · Cited by 58 · see citing works
Self-citationHemisulfur Mustard in the Palliation of Patients with Metastatic Ovarian Carcinoma
Green, T. H. (1959) · Obstetrics and Gynecology · doi:10.1097/00006250-195904000-00001 · Cited by 53 · see citing works
Howell, S. B., Kirmani, S., Lucas, W. E., Zimm, S., Goel, R., Kim, S., Horton, M., McVey, L., Morris, J., & Weiss, R. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.137 · Cited by 52 · see citing works
Peritoneal electrolyte absorption: analysis of portal, systemic venous, and lymphatic transport.
Kraft, A. R., Rk, T., & Jesseph, J. E. (1968) · PubMed · Cited by 47 · see citing works
Markman, M. M., Hakes, T. B., Reichman, B. S., Hoskins, W. J., Rubin, S. C., Jones, W., Almadrones, L., Yordan, E. L., Eriksson, J. H., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.2.204 · Cited by 45 · see citing works
Self-citationInfectious peritonitis in patients receiving intraperitoneal chemotherapy
Kaplan, R. A., Markman, M. M., Lucas, W. E., PFEIFLE, C. E., & Howell, S. B. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90461-9 · Cited by 41 · see citing works
Self-citationPharmacology of intraperitoneal infusion 5-fluorouracil and mitomycin-C.
Gyves, J. W. (1985) · PubMed · Cited by 40 · see citing works
Complications of extensive adhesion formation after intraperitoneal chemotherapy.
Markman, M. M., Cleary, S., Sb, H., & Lucas, W. E. (1986) · PubMed · Cited by 40 · see citing works
Self-citationIntraperitoneal carboplatin in the treatment of minimal residual ovarian cancer
Pfeiffer, P., Bennedbaek, O., & Bertelsen, K. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90131-4 · Cited by 39 · see citing works
Markman, M. M. (1993) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(93)90003-m · Cited by 34 · see citing works
Self-citationPhase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.
Markman, M. M., Hakes, T. B., Reichman, B. S., Lewis, J. L., Rubin, S. C., Jones, W., Almadrones, L., & Hoskins, W. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.6.978 · Cited by 31 · see citing works
Self-citationAdsorption of antineoplastic drugs following large-volume ip administration to rats.
Litterst, C. L., Torres, I. J., Arnold, S., McGunagle, D., Furner, R. L., Sikic, B. I., & Guarino, A. M. (1982) · PubMed · Cited by 31 · see citing works
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma
Chapman, P. B., Kolitz, J. E., Hakes, T. B., Gabrilove, J. L., Welte, K., Merluzzi, V. J., Engert, A., Bradley, E. C., Konrad, M., & Mertelsmann, R. H. (1988) · Investigational New Drugs · doi:10.1007/bf00175395 · Cited by 28 · see citing works
Self-citationDoerr, H. G., Sippell, W. G., Drop, S. L. S., BIDLINGMAIER, F., & Knorr, D. (1987) · Cancer · doi:10.1002/1097-0142(19871001)60:7 · Cited by 21 · see citing works
Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat.
Litterst, C. L., Jm, C., Mc, L., St, A., Dm, P., & Guarino, A. M. (1982) · PubMed · Cited by 21 · see citing works
Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer
Hacker, N. F., Berek, J. S., Pretorius, R. G., Zuckerman, J., Eisenkop, S. M., & Lagasse, L. D. (1985) · Gynecologic Oncology · doi:10.1016/0090-8258(85)90182-9 · Cited by 19 · see citing works
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614 · see citing works
Recent Advances in Stimuli-Responsive Release Function Drug Delivery Systems for Tumor Treatment
Ding, C., Tong, L., Feng, J., & Fu, J. (2016) · Molecules · doi:10.3390/molecules21121715 · Cited by 182 · see citing works
Pujade-Lauraine, É., Guastalla, J., Colombo, N., Devillier, P., François, É., Fumoleau, P., Monnier, A., Nooy, M. A., Mignot, L., Bugat, R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.343 · Cited by 158 · see citing works
Gadducci, A., Carnino, F., Chiara, S., Brunetti, I. M., Tanganelli, L., Romanini, A., Bruzzone, M., & Conte, P. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5677 · Cited by 140 · see citing works
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., Wheeler, R. H., Liu, T., Grizzle, W. E., Schlom, J., et al. (1996) · PubMed · Cited by 107 · see citing works
Phosphine-Gold(I) Compounds as Anticancer Agents: General Description and Mechanisms of Action
Lima, J. C., & Rodrı́guez, L. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011797927670 · Cited by 98 · see citing works
Rogers, B. E., McLean, S. F., Kirkman, R. L., Manna, D. L. D., Bright, S. J., Olsen, C. C., Myracle, A. D., Mayo, M. S., Curiel, D. T., & Buchsbaum, D. J. (1999) · PubMed · Cited by 91 · see citing works
Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity
Markman, M. M. (1986) · Cancer Treatment Reviews · doi:10.1016/0305-7372(86)90007-1 · Cited by 82 · see citing works
Self-citationMorgan, R. J., Doroshow, J. H., Synold, T. W., Lim, D. W., Shibata, S., Margolin, K. A., Schwarz, R. E., Leong, L., Somlo, G., Twardowski, P. W., et al. (2003) · PubMed · Cited by 74 · see citing works
Delgado, G., Potkul, R. K., Treat, J., Lewandowski, G. S., BARTER, J. F., Forst, D., & Rahman, A. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90296-2 · Cited by 73 · see citing works
Burris, H. A., Vogel, C. L., Castro, D. J., Mishra, L., Schwarz, M., SPENCER, S., Oakes, D. D., KOREY, R., & Orenberg, E. K. (1998) · Otolaryngology · doi:10.1016/s0194-5998(98)70208-6 · Cited by 70 · see citing works
OVARIAN SURFACE EPITHELIUM, OVULATION AND CARCINOGENESIS
Murdoch, W. J. (1996) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/j.1469-185x.1996.tb01283.x · Cited by 67 · see citing works
Gold Nanostructures as Photothermal Therapy Agent for Cancer
Choi, J., Yang, J., Jang, E., Suh, J., Huh, Y., Lee, K., & Haam, S. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011797927599 · Cited by 64 · see citing works
Harvat, B. L., & Jetten, A. M. (1996) · PubMed · Cited by 62 · see citing works
Experimental and clinical status of intraperitoneal chemotherapy
Los, G., & McVie, J. G. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90137-i · Cited by 61 · see citing works
Metastatic pattern in dogs with splenic haemangiosarcoma: Clinical implications
Waters, D. J., Caywood, D. D., Hayden, D. W., & Klausner, J. S. (1988) · Journal of Small Animal Practice · doi:10.1111/j.1748-5827.1988.tb01907.x · Cited by 55 · see citing works
Burris, A. H., Vogel, C. L., Castro, D. J., Mishra, L., Schwarz, M., Spencer, S. S., Oakes, D. D., Korey, A., & Orenberg, E. K. (1998) · Otolaryngology · doi:10.1177/019459989811800412 · Cited by 55 · see citing works
Intrapericardial Treatment of Neoplastic Pericardial Effusions
Martinoni, A., Cipolla, C. M., Civelli, M., Cardinale, D. M., Lamantia, G., Colleoni, M. A., de Braud, F., Susini, G., Martinelli, G., Goldhirsh, A., et al. (2000) · Herz · doi:10.1007/pl00001998 · Cited by 50 · see citing works
Shpall, E. J., Clarke-Pearson, D., Soper, J. T., Berchuck, A., Jones, R. B., Bast, R. C., Ross, M., Lidor, Y. J., Vanacek, K., Tyler, T., et al. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90079-z · Cited by 50 · see citing works
Jo, H., Youn, H., Lee, S., & Ban, C. (2014) · J. Mater. Chem. B · doi:10.1039/c4tb00643g · Cited by 49 · see citing works
Ozols, R. F., & Young, R. C. (1987) · Current Problems in Cancer · doi:10.1016/s0147-0272(87)80004-1 · Cited by 48 · see citing works
Morgan, R. J., Synold, T. W., Xi, B., Lim, D. W., Shibata, S., Margolin, K. A., Schwarz, R. E., Leong, L., Somlo, G., Twardowski, P. W., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1735 · Cited by 45 · see citing works
Pharmacokinetic–Pharmacodynamic Modeling of Methotrexate-Induced Toxicity in Mice
Lobo, E. D., & Balthasar, J. P. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10431 · Cited by 37 · see citing works
Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer
Nicoletto, M. O., Padrini, R., Galeotti, F., Ferrazzí, E., Cartei, G., Riddi, F., Palumbo, M., Paoli, M. D., & Corsini, A. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051019 · Cited by 34 · see citing works
Bruzzone, M., RUBAGOTTI, A., Gadducci, A., Catsafados, E., Foglia, G., Brunetti, I. M., Giannessi, P. G., Carnino, F., Iskra, L., Rosso, R., et al. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4689 · Cited by 33 · see citing works
Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice
Kondo, A., Maeta, M., Oka, A., Tsujitani, S., Ikeguchi, M., & Kaibara, N. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.225 · Cited by 32 · see citing works
Platinum resistance: Laboratory findings and clinical implications
Muggia, F. M., & Los, G. (1993) · Stem Cells · doi:10.1002/stem.5530110304 · Cited by 32 · see citing works
Methodologic considerations in treatment using intraperitoneal chemotherapy
Averbach, A. M., & Sugarbaker, P. H. (1996) · Cancer treatment and research · doi:10.1007/978-1-4613-1247-5_18 · Cited by 31 · see citing works
Tsujitani, S., Oka, A., Kondo, A., Katano, K., Oka, S., Saito, H., Ikeguchi, M., Maeta, M., & Kaibara, N. (1999) · Oncology · doi:10.1159/000012004 · Cited by 30 · see citing works
Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience
Elias, D. M., Dubé, P., Blot, F., Bonvallot, S., Eggenspieler, P., Sabourin, J., Ducreux, M. P., Rougier, P., & Lasser, P. (1997) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(97)90750-2 · Cited by 27 · see citing works
Shah, D. K., & Balthasar, J. P. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.01.038 · Cited by 25 · see citing works
Berrada, M., Yang, Z., & Lehnert, S. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03740-9 · Cited by 25 · see citing works
Morgan, R. J., Braly, P. D., Leong, L., Shibata, S., Margolin, K. A., Somlo, G., McNamara, M., Longmate, J., Schinke, S., Raschko, J. W., et al. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5793 · Cited by 23 · see citing works
Luftensteiner, C. P., Schwendenwein, I., Paul, B., Eichler, H. G., & Viernstein, H. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00098-4 · Cited by 23 · see citing works
Phase I/II Study of Intraperitoneal Floxuridine and Platinums (Cisplatin and/or Carboplatin)
Muggia, F. M., Jeffers, S., Muderspach, L. I., Roman, L. D., Rosales, R., Groshen, S. G., Safra, T., & Morrow, C. P. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4778 · Cited by 23 · see citing works
Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion
Tomkowski, W. Z., Szturmowicz, M., Fijałkowska, A., Filipecki, S., & Figura-Chojak, E. (1994) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01240144 · Cited by 22 · see citing works
Administration of chemotherapeutic agents
Raaf, J. H. (1994) · Supportive Care in Cancer · doi:10.1007/bf00344046 · Cited by 22 · see citing works
Popova, M. D., Trendafilova, I., Szegedi, Á., Momekova, D. B., Mihály, J., Momekov, G., Kiss, L. F., Lázár, K., & Koseva, N. S. (2017) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2017.12.005 · Cited by 21 · see citing works
Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma
Jones, E. L., Secord, A. A., Prosnitz, L. R., Samulski, T. V., Oleson, J. R., Berchuck, A., Clarke‐Pearson, D. L., Soper, J. T., Dewhirst, M. W., & Vujašković, Ž. (2006) · International Journal of Hyperthermia · doi:10.1080/02656730500515270 · Cited by 21 · see citing works
Muggia, F. M., LePoidevin, E., Jeffers, S., Russell, C. A., Boswell, W. D., Morrow, C. P., Curtin, J. P., & Schlaerth, J. B. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058132 · Cited by 20 · see citing works
Self-citationAlternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
Gray, H. J., Shah, C., Swensen, R. E., Tamimi, H. K., & Goff, B. A. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.054 · Cited by 19 · see citing works
González‐Moreno, S., Ortega‐Pérez, G., & Bayón, L. G. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21325 · Cited by 19 · see citing works
Fluoroscopically Guided Peritoneal Catheter Placement for Intraperitoneal Chemotherapy
Rundback, J. H., Gray, R. J., Buck, D. R., Dolmatch, B. L., Haffner, G. H., Horton, K. M., Jelinek, J. S., Maxwell, D. D., Steves, M. A., & Sugarbaker, P. H. (1994) · Journal of Vascular and Interventional Radiology · doi:10.1016/s1051-0443(94)71476-7 · Cited by 15 · see citing works
Cytoreductive surgery for ovarian cancer
Kecmanovic, D. M., Pavlov, M. J., Kovačević, P., Ćeranić, M., & Stamenković, A. (2003) · European Journal of Surgical Oncology · doi:10.1053/ejso.2002.1367 · Cited by 15 · see citing works
Detroz, B., Laurent, S., Honoré, P., Blaffart, F., Limet, R., & Meurisse, M. (2004) · Acta chirurgica Belgica · doi:10.1080/00015458.2004.11679577 · Cited by 13 · see citing works
Smith, D. B., Mosely, R. P., Beǵent, R. H. J., Coakham, H. B., Glaser, M. G., Dewhurst, S. E., Kelly, A., & Bagshawe, K. D. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90294-4 · Cited by 12 · see citing works
Secondary cytoreduction in epithelial ovarian cancer
Morgan, M. A., & Rubin, S. C. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00111-6 · Cited by 12 · see citing works
Self-citationLa chimiothérapie intrapéritonéale dans les cancers avancés de l’ovaire
Classe, J., Muller, M., Frenel, J., Rigaud, D. B., Ferron, G., Jaffré, I., & Gladieff, L. (2010) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2009.12.007 · Cited by 11 · see citing works
de Jong, R. S., Willemse, P. H. B., Boonstra, H., de Vries, E. G. E., van der Graaf, W. T. A., Sleijfer, D. T., van der Zee, A. G. J., & Mulder, N. H. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00516-8 · Cited by 11 · see citing works
Pujade-Lauraine, É., Guastalla, J., Colombo, N., François, É., Fumoleau, P., Monnier, A., Nooy, M. A., Mignot, L., Bugat, R., Oliveira, C. M. D., et al. (1995) · Springer eBooks · doi:10.1007/978-1-4757-0136-4_24 · Cited by 10 · see citing works
Lobo, E. D., & Balthasar, J. P. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20422 · Cited by 9 · see citing works
Intraperitoneal Catheters: Percutaneous Placement with Fluoroscopic Guidance
Kirk, I., Carrasco, C. H., Lawrence, D. D., Chuang, V. P., Richli, W. R., Charnsangavej, C., Kavanagh, J. J., Kudelka, A. P., Freedman, R. S., & Markowitz, A. B. (1993) · Journal of Vascular and Interventional Radiology · doi:10.1016/s1051-0443(93)71864-3 · Cited by 9 · see citing works
Treatment of advanced epithelial ovarian cancer: past, present and future
Hoskins, P. J. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00148-m · Cited by 8 · see citing works
Morgan, R. J., Braly, P. D., Cecchi, G. R., Leong, L., Shibata, S., Margolin, K. A., Somlo, G., McNamara, M., Longmate, J., Schinke, S., et al. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5613 · Cited by 8 · see citing works
Revathi Unni, K., Amrisa Pavithra, E., Subramanian, R., & Ks, S. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01331-7 · Cited by 6 · see citing works
PRIMARY CHEMOTHERAPY IN EPITHELIAL OVARIAN CANCER
Hurwitz, H. I., & McGuire, W. P. (1994) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(21)00312-0 · Cited by 6 · see citing works
Gynecologic Malignancies of the Elderly
Weintraub, N. T., & Freedman, M. L. (1987) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30782-1 · Cited by 6 · see citing works
Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer
Aziz, Z., Zahid, M., Ahmed, Z. V. D., & Arshad, T. (1998) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1998.tb01975.x · Cited by 5 · see citing works
Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone
Luftensteiner, C. P. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00011-3 · Cited by 5 · see citing works
Huang, Y.-W., Zeng, Z., Su, L., & Liu, J. (2012) · Tumor Biology · doi:10.1007/s13277-012-0464-6 · Cited by 2 · see citing works
Primary chemotherapy of epithelial ovarian carcinoma
OMURA, G. A., & Siller, B. S. (1994) · Seminars in Surgical Oncology · doi:10.1002/ssu.2980100409 · Cited by 2 · see citing works
Preliminary experience with a modified tenckhoff catheter for intraperitoneal chemotherapy
Nguyen, H. N., Averette, H. E., Wyble, L., Sevin, B., Donato, D. M., & Peñalver, M. (1993) · Journal of Surgical Oncology · doi:10.1002/jso.2930520408 · Cited by 2 · see citing works
Rodrı́guez, L. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011797927616
Traitement des pathologies tumorales du péritoine
Calabrese, D., Bifulco, L., Kianmanesh, R., & Msika, S. (2017)
Nanotechnological Approaches for Targeted Drug Delivery to Combat Breast and Ovarian Cancer
Rani, V., Obadat, A., Boyes, K., & Brown, N. (2026) · Springer eBooks · doi:10.1007/978-3-032-10745-9_20
- Authors
- Markman, M., Reichman, B., Hakes, T., Curtin, J., Jones, W., Lewis, J. L., Barakat, R., Rubin, S., Mychalczak, B., Saigo, P., Almadrones, L., & Hoskins, W.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Markman, Maurie
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 1993-02-15
- Volume
- 71
- Issue
- S4
- Pages
- 1565-1570
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2103862203
- Cited by
- 67
- References
- 50
- Citations by year
- 2026: 1 · 2025: 1 · 2020: 1 · 2017: 2 · 2016: 1 · 2014: 2 · 2012: 1
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 52477, P01CA052477)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- intraperitoneal chemotherapy, ovarian cancer, residual disease, platinum-based chemotherapy, regional drug delivery, complete response, mitoxantrone, paclitaxel, interferon, interleukin-2, initial chemotherapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Female, Forecasting, Humans, Injections, Intraperitoneal, Ovarian Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
